GLP-1

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

Biomea is homing in on lead asset icovamenib, a menin inhibitor designed to address the underlying cause of diabetes, and a preclinical GLP-1 agonist.

Darren Incorvaia May 5, 2025 6:59pm

Ascletis sees no benefit to high, fast oral GLP-1 dose titration

Apr 23, 2025 7:25am

Ypsomed sells diabetes business to focus on GLP-1 self-injectors

Apr 23, 2025 6:20am

Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3

Apr 17, 2025 6:45am

Pfizer axes oral GLP-1 asset, blowing hole in obesity plan

Apr 14, 2025 7:34am

R&D cost per drug up year over year: Deloitte

Mar 25, 2025 12:01am